Identification

Name
Fish oil
Accession Number
DB13961
Type
Small Molecule
Groups
Approved, Nutraceutical
Description

Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

More commonly, fish oil refers to the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [FDA Label]. In general, dietary or pharmaceutical intake of these acids is primarily the only way to increase their levels in the human body where they are overall an essential element to dietary health as they have demonstrated abilities in minimizing or preventing hypertriglyceridemia when taken as an adjunct to a healthy diet [FDA Label].

Such fish oils are available in both non-prescription and prescription-only varieties at different concentrations. For many individuals, taking non-prescription fish oils as part of their multivitamin regimen is an effective way to supplement their diets with the healthy fatty acids. However, prescription-only fish oil products are sometimes prescribed for individuals who demonstrate severe (>= 500 mg/dL) hypertriglyceridemia [FDA Label].

Furthermore, a variety of studies regarding additional potential actions of fish oil omega-3-fatty acids EPA and DHA are ongoing. Such experimental actions include inflammation modulation, cardioprotective effects, the attenuation of oxidative stress, and more. Regardless, the specific mechanisms of action for these effects have yet to be formally elucidated.

Synonyms
  • Fish oil containing omega-3 acids
  • Fish oils
  • Omega-3 fish oil
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
SmofkabivenFish oil (0.57 g) + Calcium Chloride (0.028 g) + Glucose (12.7 g) + Glycine (0.56 g) + Histidine (0.15 g) + L-Alanine (0.71 g) + L-Arginine (0.61 g) + L-Isoleucine (0.25 g) + L-Leucine (0.38 g) + L-Lysine (0.34 g) + L-Phenylalanine (0.26 g) + L-Proline (0.57 g) + L-Threonine (0.22 g) + L-Tryptophan (0.10 g) + L-Tyrosine (0.02 g) + L-Valine (0.31 g) + Magnesium sulfate (0.061 g) + Medium-chain triglycerides (1.14 g) + Methionine (0.22 g) + Nitrogen (0.8 g) + Olive oil (0.95 g) + Potassium Chloride (0.23 g) + Serine (0.33 g) + Sodium acetate trihydrate (0.17 g) + Sodium glycerophosphate (0.21 g) + Soybean oil (1.14 g) + Taurine (0.05 g) + Zinc sulfate heptahydrate (0.00066 g)EmulsionIntravenousFresenius Kabi2015-09-15Not applicableCanada
Smofkabiven Electrolyte FreeFish oil (0.57 g) + Glucose (12.7 g) + Glycine (0.56 g) + Histidine (0.15 g) + L-Alanine (0.71 g) + L-Arginine (0.61 g) + L-Isoleucine (0.25 g) + L-Leucine (0.38 g) + L-Lysine (0.34 g) + L-Phenylalanine (0.26 g) + L-Proline (0.57 g) + L-Threonine (0.22 g) + L-Tryptophan (0.10 g) + L-Tyrosine (0.02 g) + L-Valine (0.31 g) + Medium-chain triglycerides (1.14 g) + Methionine (0.22 g) + Nitrogen (0.8 g) + Olive oil (0.95 g) + Serine (0.33 g) + Soybean oil (1.14 g) + Taurine (0.05 g)EmulsionIntravenousFresenius Kabi2015-09-15Not applicableCanada
Smofkabiven PeripheralFish oil (420 mg) + Calcium Chloride (18 mg) + Glucose (7.1 g) + Glycine (350 mg) + Histidine (93 mg) + L-Alanine (440 mg) + L-Arginine (380 mg) + L-Isoleucine (160 mg) + L-Leucine (230 mg) + L-Lysine (210 mg) + L-Phenylalanine (160 mg) + L-Proline (350 mg) + L-Threonine (140 mg) + L-Tryptophan (63 mg) + L-Tyrosine (12 mg) + L-Valine (200 mg) + Magnesium sulfate (38 mg) + Medium-chain triglycerides (850 mg) + Methionine (130 mg) + Olive oil (700 mg) + Potassium Chloride (140 mg) + Serine (210 mg) + Sodium acetate trihydrate (110 mg) + Sodium glycerophosphate (130 mg) + Soybean oil (850 mg) + Taurine (32 mg) + Zinc sulfate heptahydrate (0.4 mg)EmulsionIntravenousFresenius Kabi2017-02-14Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Prenatal Plus Multivitamin Plus DHA MiniCapsFish oil + Calcium Carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Folic Acid + Ferrous fumarate + Nicotinamide + Pyridoxine + Riboflavin + Thiamine mononitrate + Tocopherol + Vitamin A + Vitamin C + Zinc oxideKitSancilio & Company, Inc.2016-11-152018-04-10Us
Tricare Prenatal DHA OneFish oil (500 mg/1) + Biotin (300 ug/1) + Cholecalciferol (800 [iU]/1) + Cupric sulfate (2 mg/1) + Cyanocobalamin (100 ug/1) + Doconexent (215 mg/1) + Docusate sodium (25 mg/1) + Folic Acid (1 mg/1) + Icosapent (45 mg/1) + Inositol nicotinate (20 mg/1) + Ferrous fumarate (27 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin C (60 mg/1) + Vitamin E (30 [iU]/1) + Zinc sulfate monohydrate (10 mg/1)Capsule, gelatin coatedOralMedecor Pharma, Llc2010-01-13Not applicableUs
International/Other Brands
Omegaven (Fresenius SE & Co. KGaA)
Categories
UNII
XGF7L72M0F
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label].

Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [6]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [11].

Associated Therapies
Pharmacodynamics

In general, the only practical method of obtaining and increasing the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fish oil omega-3-fatty acids in the body is to consume them directly from foods and/or dietary supplements [5]. Having EPA and DHA is important because they facilitate numerous important functions in the human body. As an example, such supplementation of fish oil EPA and DHA demonstrates a legitimate ability to decrease triglyceride levels as their presence in the body can act as poor substrates for the enzymes that are ordinarily responsible for triglyceride synthesis and also inhibit the esterification of other fatty acids, among other mechanisms [FDA Label].

Moreover, such fish oil acids can become important components of the phospholipids that form the structures of cell membranes [5]. Specifically, DHA is particularly high in the retina, brain, and sperm [5]. Additionally, these acids also provide energy for the body and are used to form eicosanoids - signaling molecules that have similar chemical structures to the fish oil fatty acids from which they are derived [5]. Furthermore, such eicosanoids possess wide-ranging functions in the cardiovascular, pulmonary, immune, and endocrine systems [5].

Mechanism of action

The specific mechanism of action by which the fish oil EPA and DHA acids are capable of reducing serum triglyceride levels is not yet fully understood [FDA Label]. Nevertheless, it is proposed that such omega-3-fatty acids may not be the preferred substrates of the enzyme diacylglycerol O-acyltransferase that participates in the generation of triglycerides; that they might interact with nuclear transcription factors that manage lipogenesis; or that their presence and increase in levels can cause cellular metabolism to subsequently shift toward a decrease in triglyceride synthesis and an increase in fatty acid oxidation [3]. Moreover, the EPA and DHA acids are also believed to be able to promote apolipoprotein B degradation in the liver through the stimulation of an autophagic process [3]. It may also be possible that these fish oil acids can accelerate the clearance of very-low-density lipoprotein (VLDL) particles and chylomicron [3]. The combination of all these actions results in fewer VLDL particles being assembled and secreted, which is of considerable importance as VLDL particles are the major endogenous source of triglycerides [3].

Moreover, new paradigms of how inflammation is contained and dissipated involve various newly discovered chemical mediators, resolvins, and protectins [3]. Such agents are believed to be directly involved in blocking neutrophil migration, infiltration, recruitment, as well as blocking T-cell migration and promoting T-cell apoptosis [3]. Additionally, such protectins can also reduce tumor necrosis factor and interferon secretion [3]. Of particular importance, however, is the fact that protectins and resolvins are exclusively derived from omega-3-fatty acids and that EPA is the substrate of the resolvins family and DHA can be converted to both resolvins and protectins [3]. It is believed that these effects of such fish oil acids underlie the actions that fish oil have demonstrated on eliciting stability for vulnerable inflammatory plaques [3].

Finally, fish oil acids have demonstrated certain direct electrophysiological effects on the myocardium [3]. In animal studies, it was shown that the ventricular fibrillation threshold could be increased in both animals fed or infused with omega-3-fatty acids [3]. Further studies subsequently revealed that such fatty acids could reduce both sodium currents and L-type calcium currents on a cellular and ion channel level [3]. It is consequently hypothesized that during ischemia, a reduction in the sodium ion current protects hyperexcitable tissue, and a reduction in the calcium ion current could reduce arrhythmogenic depolarizing currents - and that perhaps the use of EPA and DHA fish oil acids could facilitate such activity [3]. For the time being, however, omega-3-fatty acids in pharmaceutical supplement form have not been shown to elicit such protection against heart conditions [7].

TargetActionsOrganism
ADiacylglycerol O-acyltransferase 2
agonist
Human
AProstaglandin G/H synthase 2
inhibitor
Human
AFree fatty acid receptor 4
agonist
inhibits downstream inflammation cascades
Human
UVoltage dependent L type calcium channel
inhibitor
Human
UVoltage gated sodium channel
inhibitor
human
UFree radicalsNot AvailableHuman
UNuclear factor NF-kappa-B
regulator
Human
USterol regulatory element-binding protein 1
regulator
Human
UPeroxisome proliferator-activated receptor alpha
regulator
Human
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
UPeroxisome proliferator-activated receptor delta
regulator
Human
Absorption

The absorption process of fish oil EPA and DHA acids have been documented as being very efficient, with an absorption rate of about 95%, which is similar to that of other ingested fats [5].

Volume of distribution

The volume of distribution of EPA is documented as being approximately 82 L [1] while that of DHA is about 8,216 ml/kg in male rat animal models [2].

Protein binding

DHA demonstrates a high binding capacity with human plasma proteins at 76%-82% [2].

Metabolism

During and after absorption there are three main pathways for the metabolism of the fish oil omega-3-fatty acids: (a) the acids are transported to the liver where they are incorporated into various categories of lipoproteins and then channeled to the peripheral lipid stores, or (b) the cell membrane phospholipids are replaced by lipoprotein phospholipids and the fatty acids can then act as precursors for various eicosanoids, or (c) the majority of the fatty acids are oxidised to meet energy requirements [8, 6]. The concentration of the EPA and DHA fish oil omega-3-fatty acids in the plasma phospholipids corresponds to the EPA and DHA incorporated into the cell membranes [8, 6]. Ultimately, animal pharmacokinetic studies have shown that there is a complete hydrolysis of the ethyl ester accompanied by satisfactory absorption and incorporation of EPA and DHA into the plasma phospholipids and cholesterol esters [6].

Route of elimination

The majority of elimination of DHA is observed to be via urinary excretion at 52% of the administered dose [2].

Half life

The half-life of EPA is recorded to be about 37 hours while that of DHA is documented to be about 46 hours [FDA Label].

Clearance

The clearance of EPA is recorded to be about 548 ml/hr while that of DHA is documented to be about 518 ml/hr hours [FDA Label].

Toxicity

There have been some concerns that high doses of DHA and/or EPA (in the range of 900mg/day or EPA plus 600 mg/day of DHA or more for several weeks) could potentially reduce an individual's immune function due to the suppression of inflammatory responses [5]. However, according to the European Food Safety Authority, long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day appears to be safe [5].

Commonly reported side effects of omega-3 supplements are usually mild [5]. These include unpleasant taste, bad breath, heartburn, nausea, gastrointestinal discomfort, diarrhea, headache, and odoriferous sweat [5].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fish oil.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Fish oil.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fish oil.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Fish oil.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Fish oil.Vet Approved
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Fish oil.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fish oil.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fish oil.Approved, Experimental, Investigational
AcenocoumarolFish oil may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Fish oil.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fish oil.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Fish oil.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fish oil.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fish oil.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fish oil.Experimental, Investigational
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Fish oil.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fish oil.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fish oil.Approved
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Fish oil.Approved
AmobarbitalThe metabolism of Fish oil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Fish oil.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Fish oil.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Fish oil.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fish oil.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Fish oil.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Fish oil.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Fish oil.Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Fish oil.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fish oil.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fish oil.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fish oil.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fish oil.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Fish oil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Fish oil.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Fish oil.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Fish oil.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Fish oil.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fish oil.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fish oil.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Fish oil.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fish oil.Approved, Investigational
BarbexacloneThe metabolism of Fish oil can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Fish oil can be increased when combined with Barbital.Illicit
BazedoxifeneFish oil may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fish oil.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fish oil.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fish oil.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fish oil.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Fish oil.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fish oil.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fish oil.Approved, Vet Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Fish oil.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fish oil.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Fish oil.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Fish oil.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Fish oil.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fish oil.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fish oil.Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Fish oil.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Fish oil.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fish oil.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fish oil.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Fish oil.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Fish oil.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Fish oil.Approved
Calcium AcetateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Fish oil.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Fish oil.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fish oil.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fish oil.Approved, Vet Approved, Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Fish oil.Approved, Investigational
CaseinThe therapeutic efficacy of Fish oil can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Fish oil.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fish oil.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fish oil.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Fish oil.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fish oil.Approved, Investigational, Vet Approved
ChlorotrianiseneFish oil may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Fish oil.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Fish oil.Approved, Investigational, Vet Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fish oil.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Fish oil.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Fish oil.Approved, Investigational
CimetidineThe serum concentration of Fish oil can be increased when it is combined with Cimetidine.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Fish oil.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Fish oil.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fish oil.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Fish oil.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fish oil.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fish oil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fish oil.Approved
ClorindioneFish oil may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Fish oil.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Fish oil.Approved
Conjugated estrogensFish oil may increase the thrombogenic activities of Conjugated estrogens.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Fish oil.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Fish oil.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Fish oil.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fish oil.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fish oil.Approved, Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
DaidzeinFish oil may increase the thrombogenic activities of Daidzein.Experimental
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Fish oil.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Fish oil.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Fish oil.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Fish oil.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fish oil.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Fish oil.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Fish oil.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Fish oil.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fish oil.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Fish oil.Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Fish oil.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Fish oil.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fish oil.Approved, Vet Approved
DicoumarolFish oil may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolFish oil may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolFish oil may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fish oil.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Fish oil.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fish oil.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Fish oil.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Fish oil.Approved
DiphenadioneFish oil may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Fish oil.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Fish oil.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Fish oil.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Fish oil.Approved, Vet Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fish oil.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Fish oil.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fish oil.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fish oil.Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Fish oil.Approved
EfavirenzThe serum concentration of Fish oil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Fish oil.Approved
EpimestrolFish oil may increase the thrombogenic activities of Epimestrol.Experimental
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Fish oil.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fish oil.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Fish oil.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Fish oil.Approved
EquolFish oil may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Fish oil.Approved, Investigational
EstradiolFish oil may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateFish oil may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateFish oil may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateFish oil may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolFish oil may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedFish oil may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneFish oil may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Fish oil.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fish oil.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fish oil.Experimental
Ethinyl EstradiolFish oil may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateFish oil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fish oil.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fish oil.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Fish oil.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fish oil.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fish oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Fish oil.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fish oil.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fish oil.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fish oil.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fish oil.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Fish oil.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fish oil.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fish oil.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fish oil.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Fish oil.Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Fish oil.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Fish oil.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fish oil.Approved, Investigational
FluindioneFish oil may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fish oil.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fish oil.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fish oil.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fish oil.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fish oil.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Fish oil.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Fish oil.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fish oil.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Fish oil.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Fish oil.Approved, Investigational, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Fish oil.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Fish oil.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fish oil.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fish oil.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Fish oil.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fish oil.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fish oil.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Fish oil.Experimental
FluvoxamineFluvoxamine may increase the antiplatelet activities of Fish oil.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Fish oil.Approved, Investigational, Withdrawn
GenisteinFish oil may increase the thrombogenic activities of Genistein.Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Fish oil.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fish oil.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Fish oil.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Fish oil.Approved, Investigational, Withdrawn
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Fish oil.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Fish oil.Investigational
HexestrolFish oil may increase the thrombogenic activities of Hexestrol.Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Fish oil.Approved, Investigational
HexobarbitalThe metabolism of Fish oil can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fish oil.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fish oil.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fish oil.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fish oil.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fish oil.Approved, Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Fish oil.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fish oil.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Fish oil.Approved
IndalpineIndalpine may increase the antiplatelet activities of Fish oil.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fish oil.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fish oil.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fish oil.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Fish oil.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Fish oil.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fish oil.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fish oil.Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Fish oil.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fish oil.Experimental
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Fish oil.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fish oil.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fish oil.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Fish oil.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fish oil.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Fish oil.Approved, Investigational
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Fish oil.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fish oil.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fish oil.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fish oil.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Fish oil.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fish oil.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fish oil.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fish oil.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fish oil.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Fish oil.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fish oil.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Fish oil.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fish oil.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Fish oil.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fish oil.Approved, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Fish oil.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fish oil.Approved
MestranolFish oil may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fish oil.Approved, Investigational, Withdrawn
MethallenestrilFish oil may increase the thrombogenic activities of Methallenestril.Experimental
MethohexitalThe metabolism of Fish oil can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Fish oil.Approved, Investigational
MethylphenobarbitalThe metabolism of Fish oil can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fish oil.Approved, Vet Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Fish oil.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Fish oil.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Fish oil.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Fish oil.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fish oil.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fish oil.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Fish oil.Approved, Vet Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Fish oil.Vet Approved
MoxestrolFish oil may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fish oil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fish oil.Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Fish oil.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fish oil.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fish oil.Approved, Investigational
NafcillinThe therapeutic efficacy of Fish oil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fish oil.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fish oil.Approved, Vet Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Fish oil.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Fish oil.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Fish oil.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fish oil.Approved, Investigational
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Fish oil.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Fish oil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fish oil.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fish oil.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Fish oil.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Fish oil.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Fish oil.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fish oil.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fish oil.Investigational
NitroprussideFish oil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Fish oil.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Fish oil.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Fish oil.Approved, Vet Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Fish oil.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Fish oil.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fish oil.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fish oil.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Fish oil.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fish oil.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fish oil.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Fish oil.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fish oil.Approved, Withdrawn
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Fish oil.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Fish oil.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fish oil.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fish oil.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fish oil.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Fish oil.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fish oil.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Fish oil.Approved, Investigational
PentobarbitalThe metabolism of Fish oil can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenindioneFish oil may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Fish oil can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fish oil.Approved
PhenprocoumonFish oil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Fish oil.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fish oil.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fish oil.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fish oil.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fish oil.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fish oil.Experimental
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Fish oil.Approved
Polyestradiol phosphateFish oil may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fish oil.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Fish oil.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Fish oil.Investigational
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Fish oil.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fish oil.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fish oil.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Fish oil.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fish oil.Approved, Experimental, Investigational
PrimidoneThe metabolism of Fish oil can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fish oil.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Fish oil.Approved, Vet Approved
PromestrieneFish oil may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fish oil.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Fish oil.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Fish oil.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Fish oil.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fish oil.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fish oil.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fish oil.Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Fish oil.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Fish oil.Approved
QuinestrolFish oil may increase the thrombogenic activities of Quinestrol.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Fish oil.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Fish oil.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Fish oil.Experimental
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fish oil.Approved, Experimental, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Fish oil.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Fish oil.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Fish oil.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Fish oil.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Fish oil.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Fish oil.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fish oil.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fish oil.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Fish oil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fish oil.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fish oil.Approved
SecobarbitalThe metabolism of Fish oil can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolFish oil may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fish oil.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fish oil.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fish oil.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Fish oil.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Fish oil.Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Fish oil.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Fish oil.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Fish oil.Approved, Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fish oil.Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Fish oil.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fish oil.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fish oil.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fish oil.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fish oil.Experimental
Synthetic Conjugated Estrogens, AFish oil may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BFish oil may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Fish oil.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fish oil.Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Fish oil.Approved, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fish oil.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fish oil.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fish oil.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Fish oil.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Fish oil.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fish oil.Approved
ThiamylalThe metabolism of Fish oil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Fish oil can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Fish oil.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Fish oil.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Fish oil.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fish oil.Approved
TiboloneFish oil may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fish oil.Investigational
TioclomarolFish oil may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Fish oil.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Fish oil.Approved, Withdrawn
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Fish oil.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Fish oil.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fish oil.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fish oil.Approved
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Fish oil.Approved, Investigational, Vet Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fish oil.Approved, Investigational
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Fish oil.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fish oil.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fish oil.Experimental
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Fish oil.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Fish oil.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Fish oil.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Fish oil.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fish oil.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Fish oil.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Fish oil.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fish oil.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Fish oil.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Fish oil.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Fish oil.Approved, Investigational
WarfarinFish oil may increase the anticoagulant activities of Warfarin.Approved
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Fish oil.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fish oil.Approved, Investigational
ZeranolFish oil may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fish oil.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Fish oil.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Fish oil.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fish oil.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Fish oil.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Braeckman RA, Stirtan WG, Soni PN: Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22. [PubMed:26097787]
  2. Xie LH, Li Q, Zhang J, Weina PJ: Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats. Malar J. 2009 May 26;8:112. doi: 10.1186/1475-2875-8-112. [PubMed:19470172]
  3. Weitz D, Weintraub H, Fisher E, Schwartzbard AZ: Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010 Sep-Oct;18(5):258-63. doi: 10.1097/CRD.0b013e3181ea0de0. [PubMed:20699674]
  4. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
  5. National Institutes of Health (NIH) Office of Dietary Supplements: Omega-3 Fatty Acids Fact Sheet for Health Professionals [Link]
  6. Electronic Medicines Compendium: Omacor (omega-3-acid ethyl esters 90) Monograph [Link]
  7. NIH National Centre for Complementary and Integrative Health: Omega-3 Supplements - In Depth [Link]
  8. Australian Government Department of Health and Ageing Therapeutic Goods Administration: Australian Public Assessment Report for Omega-3-acid ethyl esters 90 [File]
  9. Smoflipid FDA Label [File]
  10. Lovaza FDA Label [File]
  11. Omacor (omega-3-fatty ethyl esters) EMA Prescribing Information [File]
External Links
Wikipedia
Fish_oil
FDA label
Download (185 KB)
MSDS
Download (47.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionCholestasis / Parenteral Nutrition1
1CompletedTreatmentColitis / Primary Sclerosing Cholangitis (PSC)1
1RecruitingSupportive CareHematopoietic Stem Cell Transplantation (HSCT)1
1, 2CompletedNot AvailableSudden Cardiac Death / Ventricular Tachycardia (VT)1
1, 2Enrolling by InvitationTreatmentParenteral Nutrition Associated Cholestasis1
1, 2RecruitingTreatmentCholestasis1
1, 2Unknown StatusPreventionTreated Hypertension1
2Active Not RecruitingPreventionAge Related Cognitive Decline / Alzheimer's Disease (AD) / Dementia, Vascular / Endothelial Dysfunction / Executive Dysfunction1
2CompletedPreventionEpilepsies1
2CompletedTreatmentAnorexia Nervosa (AN) / Feeling Anxious1
2CompletedTreatmentFatty Liver1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypertriglyceridemias1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Enrolling by InvitationTreatmentTotal Parenteral Nutrition-Induced Cholestasis2
2Not Yet RecruitingTreatmentImperforate oesophagus1
2RecruitingTreatmentCessation, Smoking / Pregnancy Related / Tobacco Use in Childbirth1
2RecruitingTreatmentCholestasis1
2RecruitingTreatmentType 2 Diabetes Mellitus1
2TerminatedTreatmentCancers / Hepatic Injury1
2TerminatedTreatmentCholestasis / Total Parenteral Nutrition-Induced Cholestasis1
2TerminatedTreatmentNeoplasm, Gastric / Neoplasms, Esophageal1
2Unknown StatusTreatmentCholestasis / Parenteral Nutrition Associated Liver Disease PNALD1
2Unknown StatusTreatmentCholestasis / Short Bowel Syndrome (SBS)1
2Unknown StatusTreatmentTotal Parenteral Nutrition-Induced Cholestasis1
2, 3CompletedTreatmentAsthma, Allergic / Bronchial Inflammation / House Dust Mite Allergy1
2, 3CompletedTreatmentCardiac Surgical Procedures / Inflammatory Reaction1
2, 3CompletedTreatmentFatty Liver / Non-Alcoholic Steatohepatitis1
2, 3CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3RecruitingTreatmentCholestasis / Cholestasis of Parenteral Nutrition / Gastroschisis / Infant, Premature, Diseases / Intestinal Atresia / Short Bowel Syndrome (SBS) / Total Parenteral Nutrition-Induced Cholestasis1
2, 3RecruitingTreatmentGastrointestinal Diseases / Parenteral Nutrition Associated Liver Disease (PNALD) / Short Bowel Syndrome (SBS)1
3CompletedPreventionCoronary Artery Disease1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias / Insulin Resistance1
3CompletedTreatmentCarcinoma Surgery / Parenteral Nutrition / Post-Operative Hospital Stay1
3CompletedTreatmentEpilepsies1
3CompletedTreatmentParents2
3CompletedTreatmentRheumatoid Arthritis1
3RecruitingTreatmentCholestasis1
3RecruitingTreatmentTotal Parenteral Nutrition-Induced Cholestasis1
3Unknown StatusTreatmentMajor Liver Surgery1
3Unknown StatusTreatmentNicotine Dependence / Tobacco Dependence1
4CompletedTreatmentAtrial Flutter / Nonvalvular Atrial Fibrillation1
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentGastrointestinal Surgery1
4CompletedTreatmentMalignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
4CompletedTreatmentNonvalvular Atrial Fibrillation3
4CompletedTreatmentParenteral Nutrition1
4CompletedTreatmentSevere Sepsis1
4RecruitingTreatmentParenteral Nutrition Associated Liver Disease (PNALD)1
4TerminatedNot AvailableSchizo-Affective Disorder / Schizophrenic Disorders1
4Unknown StatusTreatmentCritical Ill Patients in SICU1
4Unknown StatusTreatmentGastric Tumors / Neoplasms, Hepatic / Pancreatic Tumors1
Not AvailableActive Not RecruitingTreatmentHealthy Volunteers1
Not AvailableAvailableNot AvailableCholestasis of Parenteral Nutrition1
Not AvailableAvailableNot AvailableCholestasis / Liver Diseases1
Not AvailableAvailableNot AvailableCholestasis / Short Bowel Syndrome (SBS)1
Not AvailableAvailableNot AvailableCholestasis / Total Parenteral Nutrition-Induced Cholestasis1
Not AvailableAvailableNot AvailableParenteral Nutrition Associated Liver Disease (PNALD)1
Not AvailableAvailableNot AvailableParenteral Nutrition-Associated Liver Disease1
Not AvailableCompletedBasic ScienceHypertriglyceridemias1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease Patients on Hemodialysis1
Not AvailableCompletedTreatmentGastric Surgery1
Not AvailableCompletedTreatmentLiver Diseases1
Not AvailableEnrolling by InvitationBasic ScienceAtherosclerosis / General Surgery / Platelet Aggregation, Spontaneous1
Not AvailableEnrolling by InvitationSupportive CareHepatic function abnormal / Liver Diseases / Parenteral Nutrition Associated Liver Disease (PNALD)1
Not AvailableRecruitingOtherElderly Women / Sarcopenia1
Not AvailableRecruitingSupportive CareMalignant Neoplasm of Stomach1
Not AvailableRecruitingTreatmentCholestasis2
Not AvailableRecruitingTreatmentCholestasis / Cholestasis of Parenteral Nutrition / Parenteral Nutrition1
Not AvailableRecruitingTreatmentLiver Diseases1
Not AvailableRecruitingTreatmentLiver Injury1
Not AvailableTerminatedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
EmulsionIntravenous
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT).
Specific Function
2-acylglycerol o-acyltransferase activity
Gene Name
DGAT2
Uniprot ID
Q96PD7
Uniprot Name
Diacylglycerol O-acyltransferase 2
Molecular Weight
43830.475 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
Inhibits downstream inflammation cascades
General Function
Taste receptor activity
Specific Function
Receptor for medium and long-chain free fatty acids (FFAs). Signals via a G(q)/G(11)-coupled pathway. Acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, parti...
Gene Name
FFAR4
Uniprot ID
Q5NUL3
Uniprot Name
Free fatty acid receptor 4
Molecular Weight
42240.72 Da
References
  1. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
5. Voltage gated sodium channel
Kind
Protein group
Organism
human
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
6. Free radicals
Kind
Group
Organism
Human
Pharmacological action
Unknown
References
  1. Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012. [PubMed:22393325]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Regulator
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name
NFKB2
Uniprot ID
Q00653
Uniprot Name
Nuclear factor NF-kappa-B p100 subunit
Molecular Weight
96748.355 Da
References
  1. Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2. [PubMed:28760435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Regulator
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By sim...
Gene Name
SREBF1
Uniprot ID
P36956
Uniprot Name
Sterol regulatory element-binding protein 1
Molecular Weight
121673.6 Da
References
  1. Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2. [PubMed:28760435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Regulator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2. [PubMed:28760435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2. [PubMed:28760435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Regulator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2. [PubMed:28760435]

Drug created on January 17, 2018 10:17 / Updated on June 02, 2018 08:57